Your CE marking and FDA clearance are supporting documents in a Thai FDA submission. They are not substitutes for it. Thailand regulates medical devices under its own 4-class risk framework, administered by the Medical Devices Control Division (MDCD), and requires a locally incorporated Thai entity to hold every device registration. Foreign manufacturers that enter without understanding that structure lose market access to the entity that holds their license.
The most expensive errors in Thai medical device registration are made before the dossier is opened. A foreign manufacturer that appoints a distributor as its Thai license holder has effectively handed control of its Thai market access to a commercial counterparty. When that relationship deteriorates, the distributor holds the registration. License transfer under the Medical Device Act requires written consent from the current holder. Without that consent, the manufacturer starts the registration from the beginning.
Device classification is the second structural error. Thailand's classification criteria follow the ASEAN Medical Device Directive (AMDD): invasiveness, duration of body contact, intended use, and active vs. non-active status. These criteria do not map directly to FDA risk categories or EU MDR classification rules. A Class II FDA device may be a Class 3 or Class 4 device under Thai AMDD criteria. An application filed under the wrong class is rejected at screening, not corrected in place.
A third failure is submitting reformatted CE documentation as a CSDT dossier. The ASEAN Common Submission Dossier Template (CSDT) and the CE technical file share some underlying science but differ in structure, required annexes, and language obligations. Thai FDA screens for format compliance before review begins. A structurally non-compliant dossier does not advance regardless of data quality.
The commercial cost is market entry delayed by a full registration cycle. The structural cost is a license held by the wrong party with no straightforward path to recovery.
Medical devices in Thailand are regulated under the Medical Device Act B.E. 2551 (2008) as amended by the Medical Device Act (No. 2) B.E. 2562 (2019). Both acts are operative simultaneously: the 2008 Act is the foundational statute; the 2019 amendment is the current operative revision governing classification requirements, registration pathways, and establishment licensing.
The Medical Devices Control Division (MDCD) within Thai FDA, Ministry of Public Health, administers the framework. The MDCD is the single regulatory authority for device classification determinations, registration submissions, establishment license issuance, and post-market compliance oversight.
Thailand's device regulation aligns with the ASEAN Medical Device Directive (AMDD), the regional harmonization framework governing classification criteria and submission format across ASEAN member states. The AMDD uses letter-based class labels (A, B, C, D); Thailand uses numerical equivalents (1, 2, 3, 4). The structures are equivalent. Submissions follow the ASEAN Common Submission Dossier Template (CSDT), not the EU CE technical file format or the US FDA eCTD.
Thailand uses a 4-class risk-based classification system. Class determines the registration pathway, the documentation burden, the fee structure, and whether ISO 13485 certification is mandatory. Classification is based on AMDD criteria: invasiveness, duration of body contact, intended use, and active vs. non-active device status. These criteria are applied to the device as it will be used in Thailand, not as classified in another market.
Listing pathway. ISO 13485 is not required; Class 1 listing devices must follow Thai GMP guidelines. Required documentation includes device description and features, Letter of Authorization from the foreign manufacturer, and conditional sterilization or calibration reports where applicable.
Notification pathway. ISO 13485 certification is mandatory. Full CSDT dossier required. The notification pathway does not mean reduced regulatory scrutiny; it reflects the risk level of the device category, not a simplified review process.
Notification pathway. ISO 13485 certification is mandatory. The documentation burden is higher than Class 2, reflecting the elevated risk profile.
Full license pathway. ISO 13485 certification is mandatory. This is the most demanding pathway in terms of documentation, expert review, and timeline. Class 4 devices include high-risk implantables, active therapeutic devices, and products where failure has a direct life-threatening consequence.
AMDD-to-Thai class equivalence for cross-market teams: AMDD Class A = Thai Class 1; AMDD Class B = Thai Class 2; AMDD Class C = Thai Class 3; AMDD Class D = Thai Class 4. Documentation from other ASEAN markets referencing AMDD Class C is equivalent to Thai Class 3 for submission purposes.
Thai law does not permit a foreign manufacturer to hold a device registration or import products directly. Each of the following must be in place before the relevant stage of registration can proceed. None can be satisfied from outside Thailand.
A Thai-incorporated entity must be appointed as the official registrant and license holder. Only Thai nationals or Thai-incorporated legal entities can hold an Establishment License under the Medical Device Act. Foreign-owned Thai subsidiaries qualify; the foreign manufacturer itself does not. The local holder holds the registration in its own name on behalf of the manufacturer and bears full legal accountability to Thai FDA for the product's entire lifecycle: labeling, post-market compliance, variation submissions, and renewal. The choice of holder is the most consequential structural decision in Thailand device market entry.
A separate establishment license covering importation activity is required before commercial operations commence. This license must be held by the Thai local entity. An entity whose establishment license does not cover importation cannot legally receive commercial shipments.
A Letter of Authorization from the foreign manufacturer is a required submission document for all device classes. The LOA authorizes the Thai local holder to register and import the device on the manufacturer's behalf. The scope of the LOA matters: an authorization that grants excessive control over label claims, variation decisions, or licensing structure weakens the manufacturer's ability to manage its Thai registration over time.
ISO 13485 certification is mandatory for Class 2, 3, and 4 devices. It is not required for Class 1 listing devices. Thai FDA publishes ISO 13485:2016 guidance under the MDCD. The certificate must be current at submission and remain current throughout the review period. An expired or suspended ISO 13485 certificate blocks the submission for the affected device classes.
The pathway followed depends on device class. Each stage has its own requirements; a deficiency at any stage delays what follows. Review timelines vary by application complexity and MDCD workload; timeline estimates should be confirmed with current Thai FDA guidance or a qualified in-country specialist before reliance.
Determine the correct Thai FDA class under the Medical Device Act B.E. 2551 (2008) as amended B.E. 2562 (2019), applying AMDD criteria: invasiveness, duration of contact, intended use, and active vs. non-active status. Classification governs the pathway, the data package, and the fee structure. An error at this stage cannot be corrected mid-submission; misclassified applications are rejected at screening.
Appoint and verify the Thai local license holder. Confirm that the holder's establishment license is current, valid, and covers importation and distribution of the relevant device class. The holder must be fully licensed before the registration application is submitted in its name.
Confirm that the foreign manufacturer holds a current ISO 13485 certificate. Thai FDA requires this for all non-Class 1 submissions. Class 1 listing devices are subject to Thai GMP guidelines instead.
Prepare the submission in ASEAN Common Submission Dossier Template (CSDT) format. Technical documentation may be submitted in English. Application forms and Instructions for Use (IFU) for home-use devices must be in Thai. The CSDT structure differs from both the CE technical file and the US FDA eCTD; manufacturers adapting existing documentation for a Thai submission require a Thailand-specific gap analysis before filing.
Class 2 and 3 notifications and Class 4 license applications can be referred to the MDCD for expert review. Thai FDA decides this case by case on the individual dossier rather than applying it automatically: it happens rarely at Class 2, sometimes at Class 3, and often at Class 4. CE marking and US FDA 510(k) clearance are accepted as supporting documentation and carry evidentiary weight in the CSDT submission. They do not substitute for Thai FDA registration and do not by themselves reduce the expert review requirement. Manufacturers with an existing approval from Malaysia's Medical Device Authority (MDA) may qualify to bypass the external expert evaluation step under the Thailand-Malaysia bilateral medical device reliance program, in effect from May 1, 2026, applicable to Classes 2, 3, and 4 when submitted with a full CSDT dossier.
Upon approval, Thai FDA issues the registration number and the device may be lawfully imported and sold in Thailand. The commercial import license is product-specific and does not persist automatically; it must be maintained as part of the ongoing compliance structure. Post-approval obligations include adverse event reporting, registration renewal, and variation submissions for any approved product changes.
Thailand's labeling framework distinguishes between home-use and professional-use devices. The governing regulation is B.E. 2568 (2025), published in the Royal Gazette on December 22, 2025, and in force from June 20, 2026. The prior notification (B.E. 2563, 2020) allowed a 180-day post-importation window for Thai-language labeling compliance. That window is now 30 days. Manufacturers who built their importation and labeling workflows under the prior rules are out of compliance and must update those workflows immediately.
Labels must be in Thai language and clearly readable. IFU for home-use devices must be submitted in Thai. Application forms for home-use device submissions must also be in Thai. The 30-day post-importation labeling compliance window under B.E. 2568 applies from the date of importation. The home-use vs. professional-use designation is confirmed at classification; it is not a determination the manufacturer makes unilaterally.
Labels may be in Thai or English. IFU for professional-use devices may be in Thai or English. Professional-use designation covers devices intended for use by trained clinical or technical personnel in a professional setting, not by end users in a domestic environment.
CSDT technical documentation may be submitted in English. The Thai-language obligation applies specifically to labels, IFU for home-use products, and submission application forms. Manufacturers preparing submissions for home-use devices should build Thai-language document preparation into the dossier timeline from the outset.
Most Thailand medical device registration failures are structural, not technical. The underlying device data is typically sound. The failures sit in decisions made before the first submission document is prepared.
The most common failure is the license holder structure. A distributor that holds the manufacturer's Thai device registration also holds the manufacturer's Thai market access. License transfer under the Medical Device Act requires written consent from the current holder. A distributor that withholds consent leaves the manufacturer without a straightforward path to recovery other than full re-registration. This is not a Thai FDA failure; it is a contractual and structural oversight made at market entry, when relationships are new and the risk is not yet visible.
The second failure is misclassification. Manufacturers classify by analogy to their home-market system. FDA risk categories do not map directly to AMDD criteria. EU MDR classification rules are similarly not equivalent. Applications filed under the wrong class are rejected at screening. The fee is not refunded; the application restarts under the correct class, with a new timeline.
The third failure is CSDT format non-compliance. A reformatted CE technical file is not a CSDT. Thai FDA screens for structural compliance before review; a submission that does not meet CSDT format requirements does not reach the expert review stage regardless of the quality of the underlying data. The cost is not the expert review fee that was not yet paid; it is the months added to the timeline while the dossier is rebuilt and resubmitted.
The fees below come from two instruments read together. The application, licence and certificate fees are set by the Ministerial Regulation Prescribing Medical Device Fees B.E. 2563, Royal Gazette volume 138 part 13 Kor, 15 February 2021. The document evaluation and establishment assessment charges are set by the MOPH Notification on Expenses Collected from Applicants in the Medical Device Product Licensing Process B.E. 2564, Royal Gazette volume 138 special part 239 Ngo, 30 September 2021. The September 2024 notification sets maximum rates only and is not the schedule actually charged. Fees are paid to Thai FDA and are non-refundable on rejection or misclassification. Application fees not refunded on classification rejection: the application restarts under the correct class with a new timeline and a new fee.
| Class | Route | Application (THB) | Specialist Review (THB) | Certificate (THB) | Total (THB) |
|---|---|---|---|---|---|
| Class 1 — Low risk | Listing | 500 | — | 2,600 | 3,100 |
| Class 2 — Low-to-moderate risk | Notification | 1,000 | 38,000 | 10,000 | 49,000 |
| Class 3 — Moderate-to-high risk | Notification | 1,000 | 38,000 | 10,000 | 49,000 |
| Class 4 — High risk | Licensing | 1,000 | 53,000 | 20,000 | 74,000 |
Specialist review is not charged on every application. The totals above include it. Thai FDA calls for expert review case by case on the individual dossier: rarely at Class 2, sometimes at Class 3, and often at Class 4. Where no review is required, the total is 11,000 THB for Class 2 and Class 3, and 21,000 THB for Class 4. Class 1 never triggers expert review; its 2,600 THB figure combines the 2,000 THB listing receipt fee with a 600 THB data-verification charge on imported listings.
| Class | Renewal Fee (THB) | Notes |
|---|---|---|
| Class 1 | 1,000 | Certificate fee only; no renewal application fee assessed |
| Class 2 and Class 3 | 10,000 | Same as initial certificate fee; no renewal application fee assessed |
| Class 4 | 20,000 | Same as initial certificate fee; no renewal application fee assessed |
| License Type | Application (THB) | Inspection (THB) | Certificate (THB) | Total (THB) |
|---|---|---|---|---|
| Importer License | 100 | 12,000 | 4,000 | 16,100 |
| Manufacturer License | 100 | 12,000 | 2,000 | 14,100 |
| Seller License | 1,000 | 3,000 | 1,000 | 5,000 |
Late renewal penalty: 1,000 THB per day from the registration expiration date to the date the renewal application is submitted. Device registrations are valid for 5 years. Applications filed after expiry accrue this penalty from day one; there is no grace period.
Device advertising permit (ฆพ.): Any advertising of a medical device requires pre-approval from Thai FDA under the Medical Device Act before dissemination. The government fee is 3,000 THB per advertisement item: 1,000 THB filing fee plus 2,000 THB license fee, under the Ministerial Regulation Prescribing Medical Device Fees B.E. 2563, items (15) and (6)(b). Permits are valid for 3 years and are non-renewable; a new application is required at expiry. Penalty for advertising without a permit: up to 6 months imprisonment, 50,000 THB fine, or both.
We assess the holding structure before the dossier. The question of who holds the Thai device registration, under what contractual terms, and with what transfer protections is answered before any submission document is prepared. Structural errors made at market entry are expensive to correct; we address them at the point when correction is still simple.
We classify against AMDD criteria, not by analogy to FDA or CE equivalents. We prepare CSDT dossiers to Thai FDA format requirements and identify the gap between existing CE or 510(k) documentation and what the MDCD actually requires before the submission is filed, not after it is returned.
Our clients are typically experienced device manufacturers with established international registrations who are new to Thailand. Our job is to make the MDCD's requirements legible and manageable to a regulatory team that already understands what device registration means, without adding opacity in the process.